A report of improvement in five patients and a comparison involving five patients per group do not provide the same kind of evidence. A narrative review of methamphetamine-associated psychosis illustrates why that distinction matters when evaluating treatments for persistent or treatment-resistant symptoms.
Stacy and colleagues describe encouraging case reports and small treatment series alongside a pilot comparison with a null finding. Reading only the favorable observations would misrepresent the evidence the review actually presents.
What did the review investigate?
The authors searched PubMed, Google Scholar and PsycINFO for English-language literature published through April 2023. They considered randomized trials, retrospective cohorts and reviews, and checked references for additional relevant work. The paper first appeared online in May 2024 and was subsequently included in the journal’s 2025 volume.
This is a narrative synthesis, not one new treatment trial or a pooled calculation of treatment response. Its sources include human clinical observations, comparative studies and animal research. There is no single participant denominator, treatment dose or observation interval for the review as a whole.
The discussion below concerns the review’s account of persistent methamphetamine-associated psychotic symptoms. It does not present the underlying primary studies as independently reanalyzed datasets.
What did the five-person minocycline series show?
The review describes a small study of five participants with treatment-resistant methamphetamine psychosis. Its cited reference identifies the work as an open-label case series. The reported regimen was minocycline 200 mg once daily, with improvements in positive and negative symptoms and aspects of neurocognitive function, including auditory working memory, reported within two months.
Those details identify the historical observation. They do not establish a treatment recommendation or a verified response probability for other patients. The review’s summary does not supply a randomized comparator, a blinded assessment or a complete participant-level account of which outcomes improved in each individual.
Without an appropriate comparison, improvement over time cannot be attributed uniquely to the added medication. Changes in other treatment, time since methamphetamine use, clinical setting and the natural course of symptoms remain possible contributors. The case series can generate a research hypothesis while leaving that causal question unresolved.
What happened in the ten-person ECT comparison?
The review also discusses electroconvulsive therapy, or ECT. Favorable case reports and animal findings suggested potential benefit, but an Iranian pilot study involving ten patients with chronic methamphetamine-associated psychotic symptoms found no difference in Brief Psychiatric Rating Scale scores between the ECT group and the group maintained on olanzapine.
The denominator was five patients in each group, not ten patients receiving each treatment. The review identifies that very small sample as a limitation and calls for larger longitudinal studies.
A null comparison in such a small study does not establish that the treatments are equivalent. Conversely, the favorable reports cited elsewhere in the review do not erase the pilot’s null result. Both belong in an accurate description of what was known within the review’s search period.
The summary does not provide enough detail to reconstruct a full treatment protocol, estimate a reliable comparative effect or determine which subgroups might respond differently. Those omissions should remain visible rather than being filled with assumptions.
How do clozapine case reports fit?
The review notes reports of patients with antipsychotic-resistant methamphetamine-associated psychosis responding to clozapine. It identifies these as case reports, rather than a large controlled trial establishing a general success rate.
A case report can document a clinically important sequence of events. It cannot supply a denominator of all similar patients treated, including those who did not improve or whose outcomes were not published. Counting published favorable cases as if they were the only eligible cases creates an unsupported estimate of effectiveness.
The label treatment-resistant also needs context. The review’s brief summaries do not justify assuming identical prior treatment failures, adherence, duration of abstinence or coexisting conditions across the clozapine reports, the minocycline series and the ECT pilot.
Can larger acute-psychosis trials settle the persistent-symptom question?
Not automatically. In its separate discussion of acute methamphetamine-associated psychosis, the review describes a 120-patient comparison of extended-release paliperidone with risperidone. Both groups improved on the Positive and Negative Syndrome Scale, without a statistically significant efficacy difference reported between the medications.
That larger denominator belongs to a different clinical comparison and a different symptom context. It should not be added to the five-person series or ten-person pilot to make the evidence for a particular treatment of resistant symptoms appear larger.
Comparing two active treatments also answers a different question from observing an uncontrolled series or comparing treatment against placebo. Study size alone cannot remove those differences in design.
Which outcome is the treatment claim about?
Psychotic-symptom scores, cognitive test performance, methamphetamine consumption, treatment retention and longer-term functioning are different endpoints. A favorable symptom observation does not establish improvement in every other domain.
In particular, research on managing persistent psychotic symptoms should not be recast as proof of reduced methamphetamine use unless drug-use outcomes were actually measured. Nor does a person’s positive toxicology result establish that the person resembles the patients in these small clinical reports.
What is the defensible conclusion?
Within its historical evidence window, the review describes promising observations but substantial uncertainty about management of persistent and resistant symptoms. It does not provide a high-confidence ranking of the approaches discussed here.
For appraisal of a scientific opinion, the useful questions are concrete: was the evidence a case report, an uncontrolled series or a comparative study; how many people were in each group; which symptoms were measured; and were null findings retained? Keeping those details attached to a claim prevents preliminary observations from becoming an unsupported statement of established effectiveness.
Reference
Stacy P, Frantz J, Miller G, Merrill B, Gainer D. A narrative review of the pathophysiology and treatment of methamphetamine-associated psychosis. International Journal of Mental Health and Addiction. 2025;23:3837–3852. Published online May 14, 2024. doi:10.1007/s11469-024-01323-y. Historical narrative review; literature search through April 2023.
Leave a Reply